Methods for treating HCV
View Patent ↗The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).
1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV treatment-naïve patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, and said treatment lasts for 8 weeks, wherein said at least two DAAs comprise
and
and wherein Compound 1 is administered with ritonavir.
2. The method of claim 1 , wherein Compound 1, ritonavir and Compound 4 are co-formulated in a single composition and administered once daily, and Compound 2 is administered twice daily.
3. The method of claim 1 , wherein Compound 1 is administered 150 mg once daily together with 100 mg ritonavir once daily, and Compound 4 is administered 25 mg once daily, and Compound 2 is administered 400 mg twice daily.
4. The method of claim 1 , wherein said patient is infected with HCV genotype 1a.
5. The method of claim 2 , wherein said patient is infected with HCV genotype 1a.
6. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV treatment-naïve patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, and said treatment lasts for 8 weeks, and wherein said at least two DAAs comprise PSI-7977 and GS-5885.
7. The method of claim 6 , wherein said two DAAs are administered once daily.
8. The method of claim 6 , wherein said two DAAs are co-formulated in a single composition and administered once daily.
9. The method of claim 6 , wherein PSI-7977 is administered 400 mg once daily, and GS-5885 is administered 90 mg once daily.
10. The method of claim 6 , wherein said patient is infected with HCV genotype 1a.
11. The method of claim 7 , wherein said patient is infected with HCV genotype 1a.
12. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV treatment-naïve patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, and said treatment lasts for 8, 9, 10, 11 or 12 weeks, and wherein said at least two DAAs comprise Compound 1, Compound 2 and Compound 4, or said at least two DAAs comprise PSI-7977 and GS-5885.
13. The method of claim 12 , wherein said at least two DAAs comprise Compound 1, Compound 2 and Compound 4, and wherein Compound 1 is administered with ritonavir.
14. The method of claim 13 , wherein Compound 1, ritonavir and Compound 4 are co-formulated in a single composition and administered once daily, and Compound 2 is administered twice daily.
15. The method of claim 13 , wherein Compound 1 is administered 150 mg once daily together with 100 mg ritonavir once daily, and Compound 4 is administered 25 mg once daily, and Compound 2 is administered 400 mg twice daily.
16. The method of claim 13 , wherein said patient is infected with HCV genotype 1a.
17. The method of claim 12 , wherein said at least two DAAs comprise PSI-7977 and GS-5885.
18. The method of claim 17 , wherein said two DAAs are administered once daily.
19. The method of claim 17 , wherein said two DAAs are co-formulated in a single composition and administered once daily.
20. The method of claim 17 , wherein said patient is infected with HCV genotype 1a.